Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Horuk

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
The American Journal of Pathology|August 7, 2007
Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal miceBärbel Lange-Sperandio, Agnes Trautmann, Oliver Eickelberg, et al.
British Journal of Pharmacology|November 27, 2014
CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779Belinda Nedjai, Jonathan M Viney, Hubert Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 2013
Cell-autonomous regulation of neutrophil migration by the D6 chemokine decoy receptorAntal Rot, Clive McKimmie, Claire L Burt, et al.
American Journal of Respiratory Cell and Molecular Biology|September 28, 2010
The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosisXuebin Yang, William Walton, Donald N Cook, et al.
Kidney International|December 1, 2004
CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndromeVolker Vielhauer, Elias Berning, Vaclav Eis, et al.
Experimental Hematology|February 26, 2005
MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cellsYasuo Oba, Jun Won Lee, Lori A Ehrlich, et al.
Plos One|July 13, 2011
Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritisMaria C Lebre, Clarissa E Vergunst, Ivy Y K Choi, et al.
Journal of Neuroimmunology|August 12, 2009
Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosisEric Blasko, Christopher A Haskell, Stewart Leung, et al.
Clinical & Experimental Metastasis|November 7, 2006
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM modelEline Menu, Evy De Leenheer, Hendrik De Raeve, et al.
Molecular Pharmacology|October 14, 2005
Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8Christopher A Haskell, Richard Horuk, Meina Liang, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
The American Journal of Pathology|August 7, 2007
Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal miceBärbel Lange-Sperandio, Agnes Trautmann, Oliver Eickelberg, et al.
British Journal of Pharmacology|November 27, 2014
CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779Belinda Nedjai, Jonathan M Viney, Hubert Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 2013
Cell-autonomous regulation of neutrophil migration by the D6 chemokine decoy receptorAntal Rot, Clive McKimmie, Claire L Burt, et al.
American Journal of Respiratory Cell and Molecular Biology|September 28, 2010
The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosisXuebin Yang, William Walton, Donald N Cook, et al.
Kidney International|December 1, 2004
CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndromeVolker Vielhauer, Elias Berning, Vaclav Eis, et al.
Experimental Hematology|February 26, 2005
MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cellsYasuo Oba, Jun Won Lee, Lori A Ehrlich, et al.
Plos One|July 13, 2011
Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritisMaria C Lebre, Clarissa E Vergunst, Ivy Y K Choi, et al.
Journal of Neuroimmunology|August 12, 2009
Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosisEric Blasko, Christopher A Haskell, Stewart Leung, et al.
Clinical & Experimental Metastasis|November 7, 2006
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM modelEline Menu, Evy De Leenheer, Hendrik De Raeve, et al.
Molecular Pharmacology|October 14, 2005
Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8Christopher A Haskell, Richard Horuk, Meina Liang, et al.
Pageof 6